February 28, 2011

Aptiv Solutions Announces the Appointment of Michael McKelvey as Executive Vice President and Chief Operating Officer

FOR IMMEDIATE RELEASE
CONTACT: Gillian DellaCioppa
Phone: (508) 597-6238
Email: inquiry@aptivsolutions.com

GREAT FALLAS, VA — February 28, 2011 — Aptiv Solutions, a global biopharmaceutical and medical device development services company, announced today the appointment of Michael J. McKelvey, PhD as Executive Vice President and Chief Operating Officer. In this role, he is responsible for overseeing the US, European, and Japanese clinical operations as well as the information technology operations of the company.

Most recently, Dr. McKelvey was President and Chief Executive Officer of eResearchTechnology, Inc. (ERT) from June 2006 to December 2010. Prior to ERT, he worked for PAREXEL International, where he served as Corporate Senior Vice President, Clinical Research Services (CRS). He was responsible for the CRS Americas operations in addition to CRS global data management and global biostatistics and programming activities. Dr. McKelvey has also served as President of ICF Information Technology, Inc. and Senior Vice President of DRI/McGraw-Hill for Federal Government consulting and information management. He spent the first 10 years of his career with the U.S. Department of Commerce, where he served as Forecast Manager and Senior Economist in the Bureau of Economic Analysis. Dr. McKelvey holds a Ph.D. and M.A. from the Wharton School, University of Pennsylvania and an A.B. degree from Williams College. He is based in Great Falls, Virginia.

“We are very pleased to have attracted a Chief Operating Officer with the depth of experience in organizational, operational and strategic initiatives that Mike has,” said Patrick K. Donnelly, Aptiv Solutions’ Chairman and CEO. “In addition, Mike’s depth of domain experience in providing services for the pharmaceutical services industry will enable him to rapidly impact our company and to develop and refine our strategic objectives in the near future.”

Dr. McKelvey commented that, “Aptiv Solutions’ market leadership position in the design and execution of adaptive trials represents a unique opportunity to develop improved ways of bringing safe drugs to the market more cost-effectively and quickly. The proven track-record of our six companies together with the industry-leading combination of expertise, technology, and execution capabilities relating to adaptive clinical trials enables us to be a true knowledge- and technology-based CRO.”

Aptiv Solutions is a global biopharmaceutical and medical device development services company focused on recognizing, understanding and enabling clients to capitalize on rapid and fundamental changes facing companies developing products in the pharmaceutical, biotech and medical device market. Aptiv Solutions integrates the resources and expertise of six recently merged companies: Averion International, Trio Clinical Research, Fulcrum Pharma, ClinResearch, Niphix and ADDPLAN.

Aptiv Solutions provides innovative, comprehensive and proven product development capabilities, built on an extensive portfolio of services and a worldwide team of more than 700 professionals. Visit our website at www.aptivsolutions.com

Share
/app/uploads/2019/05/facebook@2x.png